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Background: MicroRNAs (miRNAs or miRs) are short non-coding RNAs that affect the expression of genes involved
in normal physiology, but that also become dysregulated in cancer development. In the latter context, studies to
date have focused on high-abundance miRNAs and their targets. We hypothesized that among the pool of
low-abundance miRNAs are some with the potential to impact crucial oncogenic signaling networks in colon
cancer.
Results: Unbiased screening of over 650 miRNAs identified miR-206, a low-abundance miRNA, as the most
significantly altered miRNA in carcinogen-induced rat colon tumors. Computational modeling highlighted the
stem-cell marker Krüppel-like factor 4 (KLF4) as a potential target of miR-206. In a panel of primary human colon
cancers, target validation at the mRNA and protein level confirmed a significant inverse relationship between
miR-206 and KLF4, which was further supported by miR-206 knockdown and ectopic upregulation in human colon
cancer cells. Forced expression of miR-206 resulted in significantly increased cell proliferation kinetics, as revealed by
real-time monitoring using HCT116 cells.
Conclusions: Evolutionarily conserved high-abundance miRNAs are becoming established as key players in the
etiology of human cancers. However, low-abundance miRNAs, such as miR-206, are often among the most
significantly upregulated miRNAs relative to their expression in normal non-transformed tissues. Low-abundance
miRNAs are worthy of further investigation, because their targets include KLF4 and other pluripotency and cancer
stem-cell factors.
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MicroRNAs (miRNAs or miRs) influence multiple stages
of cancer development, via post-transcriptional mechan-
isms that degrade or repress target messenger RNAs
(mRNAs) [1]. Several miRNAs with critical roles in early
embryonic development [2] become aberrantly expressed
in tumors [3]. For example, miR-21 is a high-abundance
miRNA upregulated in cancers of the breast, lung, colon,
liver, pancreas, prostate, esophagus, brain, and thyroid; tar-
gets of miR-21 include phosphatase and tensin homolog,
tropomyosin 1, and programmed cell death 4 [4,5].* Correspondence: rod.dashwood@oregonstate.edu
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distribution, and reproduction in any mediumEvolutionarily conserved high-abundance miRNAs,
such as miR-21, have been profiled in various human
cancers [6-8], but little is known about the role of
low-abundance miRNAs. We hypothesized that cer-
tain low-abundance miRNAs might regulate key
players in normal physiology such that, under nor-
mal circumstances, their expression is tightly
restricted.
One such candidate is miR-206. This miRNA has been
implicated in breast and lung cancer via the inhibition of
notch3 signaling, cell migration, proliferation, metasta-
sis, and invasion [9,10]. Moreover, levels of miR-206
were inversely proportional to c-met expression, an im-
portant proto-oncogene in rhabdomyosarcoma [11]. Lin
et al. [12] identified an autoregulatory feedback loop be-
tween miR-206 and Krüppel-like factor 4 (KLF4). This
zinc finger protein plays a crucial role in earlytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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promotes tumor formation in tissues such as breast and
skin [14,15], but suppresses malignancy in cervix, pros-
tate, bladder, esophagus, and colon [16-21]. Loss of the
KLF4 region on chromosome 9q is reported in 25% to
50% of sporadic colorectal cancers, and a significant de-
crease in KLF4 expression is observed in adenomas and
adenocarcinomas of the large and small intestine [22,23].
In a recent investigation of carcinogen-induced rat
colon tumors [24], we identified a loss of multiple let-7
family members coinciding with increased expression of
miRNA-binding proteins Lin28A/Lin28B, as well as the
stem-cell factors c-Myc, Sox2, Oct-3/4, and NANOG.
One notable omission from the list of downstream tar-
gets was Klf4, a well-established pluripotency factor [13].
Interestingly, among the entire set of 679 miRNAs pro-
filed in rat colon tumors, the greatest relative increase
compared with normal tissue was for the low-abundanceFigure 1 The miR-206/KLF4 axis in colon cancer. MicroRNA arrays [22] i
important roles in carcinogen-induced rat colon tumors. (A) Metacore path
highlighted KLF4 as an important target of miR-206, which was supported
PCR) assays revealed RNU6B as a suitable internal control for subsequent exmiR-206. This investigation, therefore, sought to clarify
the role of miR-206 and its putative target KLF4 in colon
cancer development. This report provides the first com-
prehensive analysis of the miR-206/KLF4 axis in parallel
studies involving a preclinical colon carcinogenesis
model, human primary colon cancers, and a panel of
human colon cancer cells.
Results
Increased miR-206 and attenuated Klf4 expression in rat
colon tumors
Among 679 unique miRNAs profiled, miR-206 was the
most dramatically altered miRNA in rat colon tumors,
exhibiting ~73-fold higher expression relative to the
corresponding normal-looking colonic mucosa (micro-
array data not shown). Metacore pathway analysis pre-
dicted multiple targets of miR-206, including KLF4
(Figure 1A), which was further supported by sequencedentified miR-206 as a low-abundance miRNA with potentially
way analysis encompassing rat, mouse, and human miRNAs
(B) by computational alignment. (C) Quantitative real-time PCR (qRT-
periments using the rat model, see Figure 2.
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these findings, we first screened a number of potential
endogenous controls, selecting RNU6B as a suitable
candidate for subsequent quantitative real-time poly-
merase chain reaction (qRT-PCR) assays (Figure 1C).
In six randomly selected rat colon tumors, miR-206
levels were expressed at higher levels, relative to the cor-
responding normal-looking colonic mucosa (Figure 2A).
These colon tumors had the predicted inverse relation-
ship with Klf4 mRNA levels, normalized to Gapdh
(Figure 2B). Specifically, for miR-206 the tumor mean±
SD was 1.8 × 10−5 ± 4.5 × 10−7 versus matched controls
2.8 × 10−6 ± 4.6 × 10−6 (P < 0.0001, n= 6). For Klf4 the
corresponding data were 0.084 ± 0.0075 in tumors versusFigure 2 miR-206 and Klf4 expression in rat colon tumors. Carcinogen
from a prior study [22] were examined for (A) miR-206 expression, normaliz
the six colon tumors shown, data bars indicate mean± SD, n= 3.0.25 ± 0.034 in normal colon (P < 0.001, n= 6). However,
we did note that one colon tumor with a high relative
level of miR-206 did not exhibit a correspondingly
reduced level of Klf4 (compare data in Figures 2A and
2B for Case 3). These data supported a possible role for
miR-206 regulating Klf4 in some but not all rat colon
tumors.
An inverse relationship between miR-206 and KLF4 in
human primary colon cancers
Based on a prior report [25], human primary colon can-
cers were first screened for a suitable endogenous con-
trol (data not shown); miR-191 was selected for
subsequent qRT-PCR analyses. There was an inverse-induced colon tumors and adjacent normal-looking colonic mucosa
ed to RNU6B, and (B) Klf4 mRNA expression normalized to Gapdh. For
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expression among the 21 human primary colon cancers
examined (Figure 3A, inset, r2 = 0.525, P < 0.05). Several
of the clinical cases had higher miR-206 in the cancer
compared with the patient-matched control (Figure 3B,
green versus black bars, respectively); see for example
Cases 1, 5, 7, 12, 14, 17, 18, and 21. However, the reverse
situation was noted in Cases 6, 8, 9, and 15 (Figure 3B).
Upon further analysis, low KLF4 mRNA levels were
detected in most colon cancers, with the exception of
Cases 3 and Case 6 (Figure 3C, normalized to GAPDH).
Western immunoblotting confirmed the attenuated KLF4
protein level in most, but not all, tumors (T) compared
with patient-matched normal (N) tissues (Figure 3C,
β-actin loading control). As noted in the rat model, the
inverse association between miR-206 and KLF4 was not al-
ways apparent; for example, Case 9 exhibited low relative
expression of both miR-206 and KLF4 in the cancer com-
pared with the patient-matched control (Figure 3B,C).
However, inspection of the data in Figures 3B and 3C
supported the general hypothesis in 12/21 (57%) of
the human primary colon cancers. For miR-206, the
tumor mean±SD was 1.8×10−4 ±1.6× 10−5 versus
1.3×10 −4 ±4.6× 10−6 in matched controls (P<0.05). For
KLF4, the corresponding data were 0.68±0.0746 in tumors
versus 1.467±0.194 in controls (P<0.01).Figure 3 Inverse association between miR-206 and KLF4 in human co
examined for KLF4 mRNA expression normalized to GAPDH, and for miR-20
r2 = 0.525, P< 0.05. (B) Expression of miR-206/miR-191 in 21 primary colon
GAPDH mRNA in the same tumors and matched controls. Representative W
β-actin.Knockdown or ectopic upregulation of miR-206 alters
KLF4 levels in human colon cancer cells
In an initial screen of human colon cancer cell lines
(Figure 4), SW48 cells had the highest constitutive levels
of miR-206 and low relative expression of KLF4, whereas
SW480 cells exhibited the highest endogenous KLF4
levels and low miR-206 expression. For the same mo-
lecular endpoints, intermediate expression was detected
in HCT116 and HT29 cells. Caco-2 cells exhibited low
endogenous levels of both miR-206 and KLF4, similar to
the non-cancer colon embryonic epithelial cell line
CCD841 (Figure 4, solid black bar).
We elected to use an intermediate expressing cell line,
HCT116, for subsequent experiments, designed to
knockdown or ectopically upregulate miR-206 (Figure 5).
A dose-dependent increase in miR-206 expression was
observed on transfecting cells with miR-206 mimic (30
to 70 nM), relative to untreated cells (black bar), vehicle
treatment (30 and 40 μl HiPerFectamine, blue bars), or
sham control (green bars). Under the same conditions,
enforced increase of miR-206 resulted in loss of KLF4
(compare orange bars in Figure 5B with those in
Figure 5A). In contrast, HCT116 cells treated with miR-
206 inhibitor had a significant reduction in miR-206 ex-
pression, and this was associated with a corresponding
increase in KLF4 (compare pink bars in Figure 5A andlon cancers. (A) Twenty-one human primary colon cancers were
6 normalized to miR-191. Inset: the inverse correlation was significant,
cancers and their patient-matched controls. (C) Expression of KLF4/
estern immunoblots are also shown for KLF4 protein normalized to
Figure 4 Constitutive expression of miR-206 and KLF4 in human colon cancer cells. (A) Inverse trends for KLF4 and miR-206 in five colon
cancer cell lines and non-transformed colonic epithelial CCD841 cells. (B) miR-206/miR-191 and (C) KLF4/GAPDH levels in five colon cancer cell
lines (green bars) and CCD841 cells (black bars); data bars indicate mean± SD, n= 3.
Figure 5 Knockdown and ectopic upregulation of miR-206 reciprocally regulates KLF4. Human HCT116 colon cancer cells were transfected
with increasing concentrations of a miR-206 mimic (graded orange-shaded bars indicating increasing miR-206), or miR-206 inhibitor (pink bars).
Black, blue, and green bars designate the various controls, as mentioned in the text. (A) miR-206/miR-191 expression and (B) KLF4/GAPDH levels
were measured as described for human primary colon cancers, see Figure 3 legend. Data bars =mean± SD, n= 3.
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between miR-206 and KLF4 in colon cancer.
Enforced increase of miR-206 levels augments
proliferation kinetics in human colon cancer cells
Eight hours after HCT116 cells were transfected with
miR-206 mimic, qRT-PCR assays corroborated the
expected increase in miR-206 levels relative to vehicle
and sham controls (Figure 6A,B). Reduced KLF4 expres-
sion was also confirmed under the same experimental
conditions (data not shown). Cells were loaded onto
E-plates (xCELLigence system, Roche) for real-time
monitoring assays [26], which revealed a significant in-
crease in cell proliferation kinetics following the enforced
increase of miR-206 levels (Figure 6C, inset, P < 0.05).
Discussion
The KLF4 protein contains both activator and repressor
domains, and can function as a positive or negative
regulator of gene expression [27-29]. Oncogenic effects
of KLF4 have been reported in breast, skin, and lung
cancers [14,15,30]. However, KLF4 also acts as a tumor
suppressor in human colon cancer development [31]. In-
formation on tumor stage was available for some, but
not all, of the human primary colon cancers examined
here, and as a consequence we could not corroborate an
early report suggesting KLF4 as a prognostic predictor
of colon cancer [20]. Prior studies in human colon can-
cer cell lines and primary colorectal cancers implicated
hypermethylation of the KLF4 gene promoter, loss of
heterozygosity, or mutation of the open reading frame
[17]. Recently, a KLF4/miR-206 autoregulatory feedback
loop was reported to regulate protein translation recip-
rocally in normal and cancer cells [12]. In thisFigure 6 Cell proliferation is increased by miR-206. (A) Experimental pr
upregulation of miR-206 expression. (C) Real-time monitoring assays usinginvestigation of rat colon tumors, human primary colon
cancers, and human colon cancer cell lines, the data
supported an inverse trend between KLF4 and miR-206.
Located on chromosome 6p12.2, miR-206 is similar in
expression and function to miR-1, but its sequence dif-
fers by four nucleotides [32]. Studies in breast cancer
models have reported tumor suppressive effects of miR-
206 due to its pro-apoptotic properties, via the inhib-
ition of notch3 signaling and cell migration [9,33] or
proliferation [10]. Furthermore, miR-206 was one of five
miRNAs that exhibited stage-dependent differential ex-
pression in human colorectal cancers [33]. Interestingly,
the latter report noted, in contrast to the current study,
that miR-206 levels were more typically attenuated
whereas let-7a was increased in the cancers. Given that
let-7 family members are normally ascribed a tumor
suppressor function, the authors speculated that a high
let-7a/low miR-206 ‘signature’ might designate colon
tumors with a unique phenotype in terms of cancer pro-
gression, compartmentalization, or microenvironment
[33]. This subset of cancers would differ from the more
typical scenario involving increased miR-206 and
reduced let-7a expression.
Loss of let-7a, and of other let-7 family members,
coincided with changes in other high-abundance miR-
NAs in the heterocyclic amine-induced rat colon tumors
examined here [24]. Interestingly, however, when the
dataset of 679 miRNAs was taken in its entirety, the
low-abundance miR-206 was identified as the most sig-
nificantly upregulated (up to 73-fold) in rat colon
tumors relative to normal colonic mucosa. In a separate
study using azoxymethane as the initiating agent, miR-
206 was also significantly upregulated (~100-fold) in rat
colon tumors [34]. The latter report did not pursueotocol for the treatment of HCT116 cells. (B) qRT-PCR data confirmed
the xCELLigence system [26]. Data bars indicate mean± SD, n= 3.
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other miRNAs. Nonetheless, we were intrigued that two
quite different colon carcinogens increased miR-206 so
dramatically in colon tumors, relative to normal colonic
mucosa.
Thus, we next examined a panel of human primary
colon cancers and detected increased miR-206 levels in
~50% of the cases. As predicted by computational mod-
eling, a significant inverse relationship was noted be-
tween miR-206 and KLF4 (Figure 3A, inset). Other
known colon cancer miRNA signatures were confirmed,
such as an increase in miR-21 and a decrease in miR-98,
but no concordance was observed for these miRNAs
and KLF4 (data not shown). To provide further proof-
of-concept, we examined a panel of human colon cancer
cell lines and noted that SW480 and SW48 cells pro-
vided the best evidence for an inverse association be-
tween miR-206 and KLF4. In cells with intermediate
constitutive levels, forced expression or knockdown of
miR-206 resulted in the expected reciprocal changes in
KLF4, and miR-206 ectopic upregulation increased cell
proliferation kinetics in real-time monitoring assays.
Interestingly, Caco-2 cells resembled non-transformed
CCD841 cells, as well as certain human primary colon
cancers (Cases 9 and 15, Figure 3), in having low expres-
sion levels of both miR-206 and KLF4. The latter signa-
ture appeared to involve slower cell proliferation and
doubling time, although further work is needed to clarify
this possibility, especially in vivo. Among the other fac-
tors that might contribute in vitro, miR-206 expression
was influenced by cell confluency, being about threefold
higher at 70% versus 20% confluency (MAP et al., un-
published data).
In contrast to these observations, cancers of the breast
and lung have been characterized as exhibiting low miR-
206 expression levels, suggesting a possible tumor sup-
pressor function [9,10,12]. Changes in the expression of
KLF4 also can be site specific, being upregulated in can-
cers of the breast, skin, and lung, but attenuated in
colon and gastric tumors [14,15,19,31]. The prior inves-
tigation of high-abundance miRNAs in rat colon tumors
highlighted a role for c-Myc, Oct-3/4, and Sox2 [24],
whereas the present work has implicated a fourth
‘defined factor’ for pluripotency, namely KLF4 [13]. Fur-
ther studies are in progress on the role of pluripotency
factors, cancer stem markers, and other potential mo-
lecular targets of the miR-206/KLF4 axis (Figure 1).
Conclusions
This investigation has focused on the possible role of
miR-206 and one of its predicted targets, KLF4, in colon
cancer development. As a low-abundance miRNA, miR-
206 might have been overlooked but for the fact that it
was the most significantly increased miRNA in rat colontumors, relative to normal colonic mucosa. An inverse
correlation was noted between miR-206 and KLF4 in a
panel of human primary colon cancers, which was sup-
ported by experimental studies involving knockdown
and ectopic upregulation of miR-206 levels in human
colon cancer cells. We conclude that among the low-
abundance miRNAs normally ignored or ‘discarded’ dur-
ing profiling studies there may be key players worthy of
mechanistic investigation, depending on the tissue and
cancer type.
Methods
Cell culture and transfection
Human colorectal cancer lines HCT116, HT29, Caco2,
SW48, and SW480 (American Type Culture Collection,
Manassas, VA) were maintained in McCoy’s 5A medium
(Invitrogen) supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Hyclone Laboratories), 100
units/ml penicillin, and 100 μg/ml streptomycin at 37°C
in 5% CO2. The human embryonal colon epithelial cell
line CCD841 was maintained in Eagle’s minimum essen-
tial medium (EMEM) according to the recommended
ATCC protocol. Each cell line was confirmed independ-
ently to be of human origin with no mammalian inter-
species contamination, and had the correct genetic
profile based on allele-specific markers (Idexx Radil,
Columbia, MO).
Transfection of HCT116 cells was performed using a
miR-206 mimic (Qiagen, Valencia, CA, USA). Cells were
seeded in 100-mm cell-culture grade Petri dishes and
transfected at 70% confluency using Qiagen HiPerFecta-
mine Transfection reagent, according to the manufac-
turer’s protocol. Final concentrations were as follows:
miR-206 mimic 30–70 nM, miR-206 inhibitor 50 and 75
nM, AllStars Negative Control 25–75 nM, or HiPerFec-
tamine 30–40 μl in 1000 μl serum-free McCoy’s 5A
medium. Untreated cells received complete media only.
Cells were harvested after 60 h for determination of
miRNA and mRNA expression.
Rat and human colon tumors
The preclinical study was approved by the Institutional
Animal Care and Use Committee (ACUP 3168). Male
F344 rats, 3–4 weeks of age, were housed in a ventilated
temperature-controlled room at 25°C with a 12 h light
and dark cycle. After acclimatization to the basal diet
(AIN-93 G), rats were treated by oral gavage with three
cycles of a heterocyclic amine carcinogen. Details of the
dosing protocol were reported elsewhere [24]. After the
last dose of carcinogen, in week 18, rats were switched
to AIN-93 M diet until the study was terminated at
52 weeks. Colon tumors and normal-looking colonic
mucosa samples were flash-frozen in liquid nitrogen and
stored at −80°C prior to miRNA isolation.
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controls were provided under an IRB-approved protocol
by Steven F. Moss and Lelia Simao (Rhode Island Hos-
pital, Providence, RI). The tumors were characterized as
late-stage adenocarcinomas, as reported by Wang et al.
[26].
MicroRNA extraction
Cells from experiments conducted in vitro were homo-
genized in ice-cold lysis buffer and flash-frozen. After
thawing, cell lysates, human and rat colon tumors, and
the corresponding matched controls were homogenized
on ice and microRNA isolation was performed using the
miRNeasy kit (Qiagen). RNA quality and integrity was
evaluated from the absorbance at 260 and 280 nm (260/
280 ratio > 1.9).
MicroRNA microarrays and computational analyses
Microarray analyses of 679 unique mature target rat
miRNAs (from miRBase version 17, http://miRBase.org)
were performed by LC Sciences (Houston, TX), as
detailed elsewhere [24]. Images were collected using a
GenePix 4000B scanner (Molecular Devices, Sunnyvale,
CA) and digitized using Array-Pro image analysis soft-
ware (Media Cybernetics, Bethesda, MD). Data were
analyzed by first subtracting the background and then
normalizing the signal using a locally weighted regres-
sion filter. Cluster plots were generated using software
from The Institute for Genomic Research.
For human primary colon cancers and their matched
controls, miR-206 and KLF4 expression values were ana-
lyzed by Benjamini-Hochberg correction using ArrayStar
software (DNASTAR, Inc., Madison, WI, USA). Scatter
plots were evaluated by simple linear regression analysis.
Interaction between the expression profiles among the
samples was compared by hierarchical cluster analyses
and line graph using ArrayStar software. A difference
with P < 0.05 was considered statistically significant.
Biological network analyses
Putative target mRNAs of miR-206 were examined via
MetaCore pathway analysis (GeneGo Inc., St Joseph, MI,
USA). For pathway enrichment analysis, P values were
calculated using the formula for hypergeometric distri-
bution, reflecting the probability of a pathway arising by
chance. Pathway maps were prioritized based on statis-
tical significance.
Validation of microRNA expression
The qRT-PCR analyses used the Qiagen miScript kit
according to the manufacturer’s instructions, with miR-
206-specific primers. RNA (~1 μg) from colon tumors
or normal controls was reverse-transcribed, and qRT-
PCR was performed in a 20 μl reaction containingmiScript Universal primer, miRNA specific-miScript pri-
mers, SYBR green mix, and template cDNA. Reactions
were conducted in triplicate and fluorescence intensities
were acquired using a LightCycler 480 II (Roche Applied
Science, Indianapolis, IN, USA). Relative miRNA expres-
sion was quantified by determining the point at which
the fluorescence accumulation entered the exponential
phase (Ct), and the Ct ratio of the target was normalized
to small nuclear RNA U6B (RNU6B) or miR-191.
Messenger RNA expression analysis
Target mRNAs were quantified by qRT-PCR and normal-
ized to glyceraldehyde-3-phosphate dehydrogenase (human
GAPDH, rat Gapdh). Briefly, 1 μg total RNA was reverse-
transcribed using SuperScript III First Strand Synthesis
Supermix Kit (Invitrogen, Eugene, OR, USA), and qRT-
PCR was conducted in a 20 μl reaction containing cDNAs,
SYBR Green I dye, and primers KLF4-F: CCAATTACC
CATCCTTCCTG,KLF4-R: CGATCGTCTTCCCCTCTTTG
(human) or Klf4–F: CAGACCTGGAAAGTGGTGG, Klf4-R:
ACCTGTGTTGCCCGCAGCC (rat). Experiments were
conducted in a Light Cycler 480 II, and the Ct ratio of the
target gene to GAPDH or Gapdh was calculated. Three
separate experiments were performed in triplicate, for
each sample.
Western immunoblotting
KLF4 protein levels were examined using the Western
immunoblotting methodology reported elsewhere, with
β-actin as loading control [24]. The primary antibody
was rabbit polyclonal KLF4 lot no. GR45275-3 (Abcam,
Cambridge, MA, USA), at 1:500 dilution.
Cell proliferation assays
Real-time cell proliferation assays were conducted using
the xCELLigence System (Roche). HCT116 human colon
cancer cells were transfected with miR-206 mimic, as
described previously. Cells transfected with mimic, ve-
hicle (HiPerFectamine), or sham negative control were
harvested at 8 h. Cells (1.5 × 103) in 100 μl serum-free
media were loaded onto the pre-soaked Roche E-plates
and measurements were taken at intervals of 10 min
[26].
Statistics
Data were plotted as mean ± SD and compared using
one-way and two-way ANOVA (Graphpad Prism 5 soft-
ware). In the figures, significant outcomes were shown
as: *P < 0.05, **P < 0.01, ***P < 0.001.
Abbreviations
ANOVA, analysis of variance; EMEM, Eagle’s minimum essential medium;
KLF4, Krüppel-like factor 4; KLF4, Human gene coding for KLF4; Klf4, Rat gene
coding for Klf4 protein; miRNA or miR, microRNA; mRNA, messenger RNA;
qRT-PCR, quantitative real-time polymerase chain reaction.
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